Bellus Health (NYSE:BLU) Coverage Initiated by Analysts at HC Wainwright
HC Wainwright assumed coverage on shares of Bellus Health (NYSE:BLU) in a research note published on Friday, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $28.00 price objective on the stock.
Other research analysts have also recently issued research reports about the stock. Cowen reiterated a buy rating on shares of Bellus Health in a report on Thursday, March 5th. TheStreet cut shares of Bellus Health from a c- rating to a d rating in a research report on Monday, June 1st. Finally, Zacks Investment Research cut Bellus Health from a buy rating to a hold rating in a report on Thursday, June 4th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $18.00.
NYSE:BLU opened at $9.96 on Friday. Bellus Health has a 1 year low of $5.45 and a 1 year high of $11.85. The stock has a 50-day moving average price of $10.38 and a two-hundred day moving average price of $9.24.
Several hedge funds and other institutional investors have recently bought and sold shares of BLU. Morgan Stanley boosted its holdings in Bellus Health by 23,075.1% during the first quarter. Morgan Stanley now owns 549,018 shares of the company’s stock worth $5,479,000 after purchasing an additional 546,649 shares during the last quarter. EAM Global Investors LLC acquired a new stake in Bellus Health in the 1st quarter valued at $5,437,000. Samsara BioCapital LLC bought a new stake in Bellus Health during the 4th quarter worth about $3,693,000. Janus Henderson Group PLC boosted its stake in shares of Bellus Health by 307.1% during the 1st quarter. Janus Henderson Group PLC now owns 138,793 shares of the company’s stock worth $1,385,000 after buying an additional 104,703 shares during the last quarter. Finally, FMR LLC grew its holdings in shares of Bellus Health by 2.4% in the 4th quarter. FMR LLC now owns 4,153,399 shares of the company’s stock valued at $31,527,000 after acquiring an additional 99,022 shares in the last quarter.
Bellus Health Company Profile
BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease.
Further Reading: Death Cross
Receive News & Ratings for Bellus Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellus Health and related companies with MarketBeat.com's FREE daily email newsletter.